"The cancer immunotherapy field is starting a new chapter, with discoveries now beginning to move from bedside back to the bench."
I began my training at the University of California San Diego and the La Jolla Institute of Immunology, where I studied the mechanisms by which CD4+ T cells support long-lived and high-affinity antibody responses to vaccines and infections. I continued on to a post-doctoral fellowship here at Genentech, exploring the role of the co-inhibitory receptor TIGIT in cancer immunosurveillance. Several TIGIT antibodies, including Genentech’s own Tiragolumab, are now in clinical development.
In 2020, I returned to Genentech as a Senior Scientist with joint appointments in the Oncology Biomarker Development and Cancer Immunology departments. I was drawn back by Genentech’s world class scientific community and by its investments into reverse translation and other emerging opportunities.
Nature. 2019;574(7779):565-570. doi:10.1038/s41586-019-1674-5
Cancer Cell. 2014;26(6):923-937. doi:10.1016/j.ccell.2014.10.018
The Oncology Reverse Translation group aims to leverage clinical data to generate new insights into mechanisms of response and resistance to cancer immunotherapies. We also seek to develop novel therapeutic targets and strategies.